SCA
PFE icon

Sulzberger Capital Advisors’s Pfizer PFE Stock Holding History

Sulzberger Capital Advisors’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-9,510
Closed -$242K – 54
2025
Q3 		$242K Sell
9,510
-2,260
-19% -$55.8K 0.27% 47
2025
Q2 		$285K Hold
11,770
– – 0.33% 44
2025
Q1 		$298K Hold
11,770
– – 0.39% 40
2024
Q4 		$312K Buy
+11,770
New +$319K 0.35% 42

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sulzberger Capital Advisors's PFE Position: Q4 2025 in Review

Sulzberger Capital Advisors sold out of Pfizer (PFE) in Q4 2025, closing a stake of 9,510 shares — an estimated $242K sold.

Sulzberger Capital Advisors first reported a position in PFE in Q4 2024 and held it in 4 quarters. The position peaked at $312K in Q4 2024. 2,906 funds tracked by Wall St. Rank hold PFE as of Q4 2025.

  • Sulzberger Capital Advisors reported no remaining Pfizer position as of Q4 2025 after selling out during the quarter.
  • Sulzberger Capital Advisors sold 9,510 Pfizer shares in Q4 2025, an estimated $242K.
  • Sulzberger Capital Advisors first reported a position in Pfizer in Q4 2024 and held it in 4 quarters.
  • Sulzberger Capital Advisors's Pfizer position peaked at $312K in Q4 2024.
  • 2,906 funds tracked by Wall St. Rank held Pfizer as of Q4 2025.

Based on Sulzberger Capital Advisors's 13F filing for Q4 2025, filed 7 Jan 2026.